Robert W. Baird Analysts Give Envision Healthcare Corporation (EVHC) a $35.00 Price Target

Robert W. Baird set a $35.00 price objective on Envision Healthcare Corporation (NYSE:EVHC) in a research report released on Tuesday morning. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Envision Healthcare Corporation from a sell rating to a hold rating in a research note on Friday, August 11th. Mizuho cut their price target on shares of Envision Healthcare Corporation from $65.00 to $57.00 and set a neutral rating on the stock in a research note on Wednesday, August 9th. KeyCorp set a $40.00 price target on shares of Envision Healthcare Corporation and gave the stock a buy rating in a research note on Tuesday. BidaskClub downgraded shares of Envision Healthcare Corporation from a sell rating to a strong sell rating in a research note on Thursday, August 17th. Finally, Oppenheimer Holdings, Inc. cut their price target on shares of Envision Healthcare Corporation from $77.00 to $40.00 and set an outperform rating on the stock in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Envision Healthcare Corporation currently has an average rating of Buy and a consensus target price of $47.57.

Envision Healthcare Corporation (EVHC) opened at $29.05 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.01. The stock has a market cap of $3,440.00, a P/E ratio of 8.80, a P/E/G ratio of 0.74 and a beta of 0.69. Envision Healthcare Corporation has a one year low of $23.77 and a one year high of $74.75.

Envision Healthcare Corporation (NYSE:EVHC) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.08). The firm had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Envision Healthcare Corporation had a negative net margin of 6.39% and a positive return on equity of 4.88%. The business’s quarterly revenue was up 142.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.13 EPS. research analysts forecast that Envision Healthcare Corporation will post 2.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Robert W. Baird Analysts Give Envision Healthcare Corporation (EVHC) a $35.00 Price Target” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/robert-w-baird-analysts-give-envision-healthcare-corporation-evhc-a-35-00-price-target/1783017.html.

Envision Healthcare Corporation announced that its board has initiated a stock repurchase program on Monday, September 18th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to reacquire up to 4.5% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Institutional investors have recently added to or reduced their stakes in the company. Exane Derivatives acquired a new stake in shares of Envision Healthcare Corporation in the third quarter worth $475,000. Honeywell International Inc. increased its position in shares of Envision Healthcare Corporation by 17.4% in the third quarter. Honeywell International Inc. now owns 542,100 shares of the company’s stock worth $24,367,000 after acquiring an additional 80,200 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Envision Healthcare Corporation by 5.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 632,195 shares of the company’s stock worth $39,620,000 after acquiring an additional 33,587 shares in the last quarter. Stonebridge Capital Management Inc. increased its position in shares of Envision Healthcare Corporation by 87.0% in the third quarter. Stonebridge Capital Management Inc. now owns 30,329 shares of the company’s stock worth $1,364,000 after acquiring an additional 14,111 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in shares of Envision Healthcare Corporation in the second quarter worth $797,000.

About Envision Healthcare Corporation

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare Corporation (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Red Sox Want Sluggers, Giancarlo Stanton May Become Available


Leave a Reply

 
© 2006-2017 BBNS.